{"name": "InterMune",
 "permalink": "intermune",
 "crunchbase_url": "http://www.crunchbase.com/company/intermune",
 "homepage_url": "http://www.intermune.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "ir@intermune.com",
 "phone_number": "(415) 466-2200",
 "description": "",
 "created_at": "Thu May 24 03:07:22 UTC 2012",
 "updated_at": "Thu May 24 03:08:24 UTC 2012",
 "overview": "\u003Cp\u003EInterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases.  In pulmonology, we are focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.  Pirfenidone, the only medicine approved for IPF anywhere in the world, is approved for marketing by InterMune in the EU as Esbriet\u00ae and is currently in a Phase 3 clinical trial to support regulatory registration in the United States.  InterMune\u0026#8217;s research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. \u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[149,
       23],
      "assets/images/resized/0019/1369/191369v1-max-150x150.png"],
     [[149,
       23],
      "assets/images/resized/0019/1369/191369v1-max-250x250.png"],
     [[149,
       23],
      "assets/images/resized/0019/1369/191369v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "Member Board of Directors",
    "person":
     {"first_name": "Frank",
      "last_name": "Verwiel",
      "permalink": "frank-verwiel",
      "image":
       {"available_sizes":
         [[[80,
            95],
           "assets/images/resized/0026/6452/266452v1-max-150x150.jpg"],
          [[80,
            95],
           "assets/images/resized/0026/6452/266452v1-max-250x250.jpg"],
          [[80,
            95],
           "assets/images/resized/0026/6452/266452v1-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": true,
    "title": "",
    "person":
     {"first_name": "Curtis",
      "last_name": "Ruegg",
      "permalink": "curtis-ruegg",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$0",
 "funding_rounds":
  [],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "3280 Bayshore Blvd.",
    "address2": "",
    "zip_code": "94005 ",
    "city": "Brisbane",
    "state_code": "CA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "InterMune to Divest Actimmune\u00ae (Interferon Gamma-1b)",
    "stoned_year": 2012,
    "stoned_month": 5,
    "stoned_day": 23,
    "source_url": "http://phx.corporate-ir.net/phoenix.zhtml?c=100067\u0026p=irol-newsArticle\u0026ID=1698355\u0026highlight=",
    "source_text": "",
    "source_description": "InterMune to Divest Actimmune\u00ae (Interferon Gamma-1b)",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "InterMune",
      "permalink": "intermune"}}],
 "ipo":
  {"valuation_amount": null,
   "valuation_currency_code": "USD",
   "pub_year": null,
   "pub_month": null,
   "pub_day": null,
   "stock_symbol": "NASDAQ:ITMN"},
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}